What Is Aktis Oncology, Inc. (AKTS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Aktis Oncology, Inc. at its current price of $25.02. The composite intrinsic value is estimated at $15.43 (-38.3% average return), with 5 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +64.7% (fair value: $41.21), while Regime Cross is the most conservative at -98.7% ($0.34). The spread between these extremes — +163.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About AKTS?
8 of 13 models are currently active for AKTS. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates AKTS's intrinsic value at $6.63, implying -73.5% downside from the current price. See which stocks rank higher →
How Does AKTS Rank in Biotechnology?
Among 64 Biotechnology stocks, AKTS ranks #63 by Quality of Company score. CirclFi's QOC score of 1.9/10 evaluates 32 fundamental signals. A score of 1.9 signals below-average fundamentals.
See all Most Undervalued Biotechnology Stocks →
Within the Biotechnology space, Aktis Oncology, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is AKTS a Value Trap?
The Value Trap algorithm is not active for AKTS. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Aktis Oncology, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Aktis Oncology, Inc. is rated at 1.9/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +163.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AKTS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AKTS's 8 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad